¡Ya estamos en ! Descubre más
AMYT

Amryt Pharma plc American Depositary Shares

Excluida de cotización

AMYT dejó de cotizar en bolsa el 11 de abril de 2023.

 

Acerca de: Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).

Empleados: 289

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 0%
Neutral 0%
Negativo 0%

No hemos recibido artículos de noticias recientes sobre AMYT.

Gráficos de precios implementados con Lightweight Charts™